

28<sup>th</sup> June, 2016

The Manager, Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Fax No.:022-26598237 / 38  
NSE Symbol: PANACEABIO

Bombay Stock Exchange Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
Fax No.:022-22721919, 3121  
BSE Scrip Code: 531349


**Re.: Press Release - Panacea Biotec Launches – TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)**

Dear Sir,

We wish to inform you that the Company has introduced indigenously developed high quality antidiabetic drug, TENEPAN (Teneligliptin), for treatment of **Type 2 Diabetes Mellitus (T2DM)**. TENEPAN (Teneligliptin), a DPP4 inhibitor, aims to improve accessibility of this treatment for the benefit of patients at an affordable cost as part of our commitment to Government of India's "MAKE IN INDIA" mission.

A copy of the Press Release titled "Panacea Biotec Launches – TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM) being issued to the media, etc. is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Thanking you,  
Sincerely yours,  
for **Panacea Biotec Ltd.**



**Devender Gupta**  
**Chief Financial Officer and Head IT**

Encl. : As above

B1 Extn. /G3, Mohan Co-op Indl. Estate,  
Mathura Road, New Delhi -110044  
Email: vinodgoel@panaceabiotec.com  
Phone: D.I.D. +91-11-4167 9015  
Fax: +91-11-4167 9075

**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Press Release:

For Immediate Distribution

**Panacea Biotec Launches – TENEPAN**  
**A Cost Effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)**

**New Delhi, 28<sup>th</sup> June, 2016:** Panacea Biotec, India's 3<sup>rd</sup> largest biotechnology company introduces indigenously developed high quality antidiabetic drug, **TENEPAN** (Teneligliptin), for treatment of **Type 2 Diabetes Mellitus (T2DM)**.

**TENEPAN** (Teneligliptin) aims to improve accessibility of this treatment for the benefit of patients at an **affordable cost** as part of our commitment to Government of India's **"MAKE IN INDIA" mission**.

**Dr. Rajesh Jain**, Jt. Managing Director, Panacea Biotec Limited said, "Panacea Biotec has always endeavored to partner with Medical Practitioners in assisting to manage their patients better by introducing **New, Innovative and Good Quality products**."

Panacea Biotec will remain committed to its mission **"Innovation in Support of Life"** and continue to provide the Latest and Most Affordable preventive and therapeutic care to patients across the globe.

With this endeavor in mind, Panacea Biotec has its presence in the Diabetes market through Diacar Alpha Business team which is ranked 3<sup>rd</sup> as per sales (MAT Mar'16) and 5<sup>th</sup> as per the prescriptions (CMARC Nov-Feb'16) in its operating market. Panacea Biotec is the leader in the Gliclazide market with its brand Glizid-M which was awarded the "Brand of the Year" in the chronic segment; in the 2015 AWACS Marketing Excellence Awards Function.

With the launch of **Tenepan** (Teneligliptin), a DPP4 inhibitor, molecule which works in synergy with the **Sulphonylureas** to manage patients uncontrolled on Metformin therapy and/or a **Sulphonylurea** therapy; in our case, gliclazide (Glizid, Glizid MR, Glizid M OD); we intend to reach out to the patients with the latest therapeutic





**Panacea Biotec**

*Innovation in support of life*

treatment for Diabetes via 38,000 Doctors (including Diabetologists, Endocrinologists and Consulting Physicians with Diabetes practice) and achieve our goal to become the No. 1 company in our Diabetes operating market, **said Dr. Rajesh Jain.**

Diabetes mellitus (T2DM) is the most common metabolic disorder. Prevalence of diabetes is rapidly increasing and as per the published data in 2015, and has affected 69.1 million people in India and 415 million people worldwide. Diabetes is recognized as a major health problem predisposing patients to small- and large blood vessels complications including heart disease, kidney failure (nephropathy) and vision damage (retinopathy). Today, diabetes poses an immense global challenge and leading cause of death. Once diagnosed, the diabetic patients need life-long medications which are recommended by their physician, to keep the blood glucose levels within normal range. To achieve this, the 'drug of choice' is based on patient, disease, and drug characteristics, with the goal of reducing blood glucose levels while minimizing side effects, especially hypoglycemia (below normal, low blood glucose levels).

Dipeptidyl peptidase-4 (DPP-4) inhibitors are important treatment options available in this decade for the management of diabetes, which modify various elements of the disease, including increased secretion of glucagon, post-lunch hyperglycemia (high blood glucose levels), and, possibly, pancreatic *beta*-cell dysfunction. Importantly, DPP-4 inhibitors increase glucagon-like peptide-1 (GLP-1) availability and correct the "incretin defect" seen in T2DM patients. This is unique and different mechanism of action compared to other anti-diabetic drugs. DPP-4 inhibitors reduce effectively fasting, post-lunch blood glucose levels (signify immediate control) and HbA1c levels (signify long-term control). DPP-4 inhibitors have gained worldwide acceptance, in particular the possibility of becoming the preferred therapy for T2DM due their excellent tolerability profile, with a low risk of hypoglycemia, a neutral effect on body weight, and once-daily dosing.

**Tenapan (Teneligliptin)**, a novel DPP-4 inhibitor, has unique structure characterized by five consecutive rings, which produce a potent, selective and long-lasting effect. Teneligliptin also significantly enhances insulin secretion and improves insulin sensitivity without causing hypoglycemia or weight gain. The safety profile of Teneligliptin in kidney and liver failure is better than other available DPP-4 inhibitors. It is eliminated from the body via kidney as well as liver. So that, no dose adjustment is necessary in patients with kidney and liver failure. Various studies have shown that



**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.

e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com



**Panacea Biotec**

*Innovation in support of life*

**Teneligliptin** is effective and safe when taken as a monotherapy. It is recommended to use in newly diagnosed patients and as an add-on therapy in patients uncontrolled on Metformin or Sulfonylurea therapy.


In diabetes, a significant number of patients, particularly those with more long-standing disease, high carbohydrate diet, central obesity and sedentary life-style do not achieve near-normal glucose levels with one or two drugs (Sulfonylurea and Metformin alone or in combination), in such cases drugs with different actions have been used to attack the 'internal defects' of diabetes at multiple points to control blood glucose levels.

Initially patients are treated with one drug e.g. Sulfonylurea (Gliclazide – Glizid / Glizid MR) or combinations e.g. Gliclazide plus Metformin (Glizid-M/ Glizid-M OD) or with Voglibose (Glizid-MV). As mentioned above, when the diabetes is not in control despite of one drug or combination therapy, it is most essential to treat patients with DPP-4 inhibitor like **Teneligliptin**. The last two year studies have confirmed that **Teneligliptin** is effective and safe when added to Metformin and / or other antidiabetic agents in combination therapy to control blood glucose levels and reduce HbA1c levels. Also, it has multiple beneficial actions to address the 'internal defects' of diabetes.

### **Notes to the Editors**

#### **About Panacea Biotec**

Panacea Biotec is one of India's leading research based biotechnology company with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 3 biotechnology companies (Biospectrum – ABLE Survey, July 2014) and the top 50 pharmaceutical companies (AIOCD AWACS – MAT May 2016) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of Oncology, Organ Transplantation, Nephrology, Diabetes, Osteoporosis, and Pediatric Immunization Vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro particles, liposomes, gastro-retentive systems. Panacea Biotec has introduced its products in 22 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. Panacea Biotec has research collaborations with leading national and international research organizations and corporations. Panacea Biotec's





**Panacea Biotec**

*Innovation in support of life*

state of the art manufacturing facilities for Vaccines and Pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2900 employees including around 125 scientists working across 4 R&D centers of the company.

**For more information, please contact -**

**Mr. P. D. Karan**



**Vice President - Business Diversification & Corporate Communication**

**B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,**

**Mathura Road, New Delhi - 110044, INDIA**

**Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)**

**Fax + 91 11 41578002**

**Mobile: + 91 9312693040, + 91 9810500539**

**Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com)**

**Web: [www.panaceabiotec.com](http://www.panaceabiotec.com)**